2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2025)

Continuous glucose monitoring (CGM) is transforming diabetes care in both type 1 diabetes (T1D) and type 2 diabetes (T2D), with or without insulin use, said Dr Pratik Choudhary, Honorary Consultant and Professor at the University of Leicester, UK, during an Abbott-sponsored symposium at ATTD-Asia 2025 in Singapore.

A real-world assessment of tirzepatide in Indian clinical practice has shown significant glycaemic and weight benefits in adults with type 2 diabetes (T2D). The medication is also well tolerated, with manageable gastrointestinal side effects, and highly accepted by patients.

A real-world study from India shows that multiple drug combinations effectively controlled blood sugar levels in individuals with type 2 diabetes (T2D).

Findings from the prospective PRIMARY-INDIA study presented at ATTD-Asia 2025 show clinically meaningful improvements in glycaemic control with insulin glargine in individuals with type 2 diabetes (T2D) in primary care settings, with a consistent safety profile.